Unum Therapeutics Inc (NASDAQ:UMRX) has been assigned an average rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $17.25.
A number of research analysts have commented on the company. Zacks Investment Research downgraded Unum Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 21st. HC Wainwright started coverage on Unum Therapeutics in a report on Thursday, December 20th. They issued a “buy” rating and a $18.00 price target on the stock. Cowen started coverage on Unum Therapeutics in a report on Tuesday, February 26th. They issued a “market perform” rating on the stock. Finally, SunTrust Banks cut their price target on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a report on Friday. They noted that the move was a valuation call.
In related news, insider Seth Ettenberg sold 11,485 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $4.12, for a total value of $47,318.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
NASDAQ:UMRX opened at $4.39 on Friday. Unum Therapeutics has a 52 week low of $3.60 and a 52 week high of $17.66.
Unum Therapeutics (NASDAQ:UMRX) last released its earnings results on Thursday, March 28th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Unum Therapeutics had a negative return on equity of 382.71% and a negative net margin of 404.34%. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $2.58 million. On average, sell-side analysts anticipate that Unum Therapeutics will post -1.44 earnings per share for the current year.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
See Also: Bid-Ask Spread
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.